Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients

This study is currently recruiting participants.

Verified by Hospital Authority, Hong Kong, June 2008

Sponsors and Collaborators:	Hospital Authority, Hong Kong The University of Hong Kong Fresienius Kabi HK Ltd
Information provided by:	Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:	NCT00563498

Purpose

The primary purpose of this project is to investigate if addition of glutamine, an amino acid, to standard parenteral nutrition, may improve the clinical outcome of the bone marrrow transplantation reducing the occurrence of veno-occlusive disease and severity of mucositis.

Condition	Intervention
Pulmonary Veno-Occlusive Disease Hepatic Veno-Occlusive Disease Mucositis	Drug: Glutamine

MedlinePlus related topics: Bone Marrow Transplantation

Drug Information available for: Glutamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-Occlusive Disease and Mucositis.

Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:

Veno-occlusive disease [ Time Frame: 1 month ]
Mucositis [ Time Frame: 1 month ]

Secondary Outcome Measures:

Hospital stay [ Time Frame: 2 months ]
Use of antibiotics [ Time Frame: 2 months ]

Estimated Enrollment:	40
Study Start Date:	July 2004
Estimated Study Completion Date:	June 2006

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as conditioning.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00563498

Contacts

Contact: YH Leung, Dr

(852) 2855 3347

ayhleung@hku.hk

Locations

China
Queen Mary Hospital	Recruiting
Hong Kong, China
Sub-Investigator: YH Leung, Dr
Sub-Investigator: Raymond Liang, Prof

Sponsors and Collaborators

Hospital Authority, Hong Kong

The University of Hong Kong

Fresienius Kabi HK Ltd

Investigators

Principal Investigator:

Albert Lie, Dr

Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong

More Information

HAREC Clinical Trial Registry This link exits the ClinicalTrials.gov site

Study ID Numbers:	EC1432-00, HARECCTR0500034
Study First Received:	November 21, 2007
Last Updated:	December 15, 2008
ClinicalTrials.gov Identifier:	NCT00563498
Health Authority:	Hong Kong: Ethics Committee

Keywords provided by Hospital Authority, Hong Kong:

Veno-occlusive disease
Mucositis

Study placed in the following topic categories:

Mouth Diseases
Pulmonary veno-occlusive disease
Hepatic venoocclusive disease
Liver Diseases
Mucositis
Gastrointestinal Diseases
Vascular Diseases
Hepatic Veno-Occlusive Disease

Pulmonary Veno-Occlusive Disease
Digestive System Diseases
Respiratory Tract Diseases
Lung Diseases
Pulmonary venoocclusive disease
Stomatognathic Diseases
Gastroenteritis

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009